Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB2916 Injection in Patients With Advanced Malignant Tumors
NCT05213767
·
clinicaltrials.gov ↗
PHASE1
Phase
UNKNOWN
Status
190
Enrollment
INDUSTRY
Sponsor class
Conditions
Advanced Tumors
Interventions
DRUG:
TQB2916 injection
Sponsor
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.